Retatrutide Dosage Chart: Complete Guide to Safe Titration Protocols

Introduction

A retatrutide dosage chart maps the weekly titration schedule used in clinical trials to gradually increase this investigational triple-agonist peptide from a lower starting dose to a target maintenance dose over 16 to 20 weeks. If you're searching for one, here's what you need to know first: you should not be following a retatrutide dosage chart on your own. As of June 2026, Lilly says retatrutide is not FDA-approved, remains investigational, and is legally available only through Lilly's clinical trials.

This guide covers the doses studied in Phase 2 and Phase 3 clinical trials, explains why gradual dose escalation exists, breaks down the dose escalation schedule week by week, and-critically-makes the case for why attempting to self-administer retatrutide from unregulated "research only" sources is medically dangerous and legally risky. The target audience is patients comparing GLP-1 and next-generation weight-loss options who want to understand what trial dosing teaches, without mistaking a trial chart for personal medical instructions.

By reading this guide, you will:

• Understand the clinical trial-based titration process and why each dose step exists

• See detailed dosage charts comparing different doses of retatrutide across trial protocols

• Learn why jumping straight to a high dose is dangerous for your digestive system and overall health

• Recognize the serious risks of research-only and black-market retatrutide products

• Know when to discuss approved alternatives, clinical-trial enrollment, or future lawful access with a licensed clinician

Understanding Retatrutide Dosage Charts

A retatrutide dosage chart is a structured timeline showing the weekly dose increase from an initial starting dose of retatrutide through several intermediate steps to a target dose. These charts originate entirely from Eli Lilly's clinical trial protocols-they are not FDA-approved prescribing labels, because retatrutide has not yet received regulatory approval for any indication. Understanding these charts matters because the titration process directly determines both how effectively the drug works and how safely your body can adjust to its powerful metabolic effects.

What Makes Retatrutide Different

Retatrutide (LY-3437943) is Lilly's triple agonist-it simultaneously activates three hormone pathways: GLP-1 receptors, glucose dependent insulinotropic polypeptide (GIP) receptors, and glucagon receptors. This triple mechanism separates it from single-agonist medications like semaglutide (GLP-1 only) and dual-agonist drugs like tirzepatide (GLP-1 + GIP). The glucagon receptor activation adds a unique dimension: it burns energy by increasing energy expenditure and mobilizing body stores of fat, but it also amplifies gastrointestinal side effects and can affect liver function and blood sugar regulation.

Because retatrutide engages all three pathways simultaneously, the body needs time to adjust. This is why gradual dose escalation-called titration-is not optional. Jumping straight to 12 mg without allowing your body time to acclimate would dramatically increase the risk of severe nausea, vomiting, diarrhea, and potentially dangerous changes in metabolic health. The drug's half-life of approximately 5 to 6 days supports once weekly dosing, but it also means each dose increase compounds effects over several weeks.

Clinical Trial vs. Real-World Prescribing

There is a critical difference between clinical research protocols and real-world prescription medicine. In trials, participants are carefully screened, monitored with frequent lab work (including liver enzymes, kidney function, lipid panel, and HbA1c), and followed by research teams. The dosage charts from these trials represent controlled conditions with strict inclusion criteria-for example, the Phase 2 trial published in the New England Journal of Medicine enrolled 338 adults with BMI ≥30 (or ≥27 with comorbidities) but excluded those with type 2 diabetes.

As of June 2026, retatrutide remains investigational. Lilly describes it as not currently FDA-approved and legally available only through Lilly's clinical trials. FDA has also warned consumers about unapproved GLP-1 products, including products containing retatrutide, sold directly to consumers with research-use or not-for-human-consumption language. The dosage charts below are models derived from trial data-not prescriptions you should follow independently.

Standard Retatrutide Titration Schedules

Clinical trials have tested multiple dose escalation schedules across Phase 2 and Phase 3 programs. The consistent principle: participants began at a lower starting dose and gradually increased by approximately 2 to 3 mg every four weeks until reaching their target maintenance dose. This 4-week interval allows the body adjust to each new dose level before the next dose increase.

Phase 3 TRIUMPH Trial Schedule

The TRIUMPH Phase 3 program refined the escalation pattern to be smoother than Phase 2, adding an intermediate 6 mg step that was absent in earlier protocols. For the 12 mg target dose arm, the dosing schedule follows this structure:

Weeks 1 to 4: 2 mg starting dose. Every patient begins here regardless of body weight. This initial phase establishes baseline tolerability, lets you and your physician identify early adverse events, and begins the process of appetite suppression. The first few weeks are about letting your body adjust-not about dramatic weight loss results.

Weeks 5 to 8: 4 mg dose escalation. The first dose increase doubles the initial amount. Efficacy begins to increase noticeably-trial data showed even the 4 mg maintenance arm produced substantial weight loss over time (~19% body weight at 80 weeks in TRIUMPH-1). Side effect monitoring intensifies here.

Weeks 9 to 12: 6 mg intermediate step. This step is a key improvement in Phase 3 design. Phase 2 protocols jumped from 4 mg directly to 8 mg, which increased GI complaints. The 6 mg intermediate allows a more gradual transition and reduced the severity of gastrointestinal side effects during dose escalation.

Weeks 13 to 16: 9 mg high dose step. At this dose level, significant weight loss accelerates. In TRIUMPH-4, the 9 mg arm achieved approximately 26.4% weight loss in completers over 68 weeks. Heart rate monitoring becomes particularly important, as increases were noted peaking around 24 weeks in trial data.

Week 17+: 12 mg maximum dose maintenance. This is the highest dose of retatrutide studied in humans. Participants on 12 mg in TRIUMPH-1 lost an average of approximately 70.3 lb (28.3% of body weight) over 80 weeks. This dose is maintained indefinitely for continued efficacy, with ongoing monitoring of organ function, metabolic markers, and side effects.

Alternative Dosing Considerations

Not every patient needs-or can tolerate-the maximum dose. Trial data demonstrates a clear dose dependent effect on both efficacy and side effects, which means lower maintenance doses offer a meaningful trade-off:

• 4 mg maintenance: In TRIUMPH-1, participants on the 4 mg dose lost approximately 47.2 lb (19% of body weight) over 80 weeks, with notably fewer adverse events and lower discontinuation rates.

• 9 mg maintenance: The dose escalation schedule follows the same initial steps (2 → 4 → 6 → 9 mg) but stops at 9 mg rather than continuing to 12 mg.

• Slower titration: Some protocols allow 6-week intervals between dose steps for patients who experience persistent nausea or other GI distress. While less validated in formal trials, this approach appears in clinical practice for sensitive individuals.

Individual response varies significantly. BMI, sex, baseline metabolic health, liver function, and concurrent use of other medications all influence how someone responds to each dose level. This is precisely why dosing decisions must be made by a physician who can evaluate your specific situation-not by following a chart you found online.

Detailed Dosage Chart Implementation

Building on the titration schedules above, here is what a comprehensive retatrutide dosing protocol looks like in practice-including the monitoring requirements that make physician supervision absolutely essential.

Weekly Administration Protocol

Retatrutide is given as a once weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm. The injection day should remain consistent (same day each week). Each dose step requires specific medical oversight:

1. Initial 2 mg dose (Weeks 1 to 4): Baseline labs established before first injection-complete metabolic panel, liver enzymes, kidney function, lipid panel, HbA1c, and fasting glucose. Monitor for initial GI tolerance and blood sugar changes.

2. 4 mg escalation (Weeks 5 to 8): Physician assesses tolerability at the 2 mg level before authorizing the increase. Side effect tracking for nausea, changes in gastric emptying, and appetite suppression intensity.

3. 6 mg intermediate dose (Weeks 9 to 12): Follow-up labs to check liver function and kidney function. Evaluate whether gradual dose increases are being tolerated or if the patient needs to hold at 4 mg longer.

4. 9 mg high-dose monitoring (Weeks 13 to 16): Heart rate assessment, repeat metabolic labs. Significant weight loss typically accelerating. Evaluate drug interactions with other medications.

5. 12 mg maximum dose (Week 17+): Comprehensive lab panel repeated. Long term success depends on sustained monitoring-the Phase 3 trials continued for 68 to 80 weeks with regular clinical oversight.

Dosage Chart Comparison Table

The weight loss results across different doses also reveal important patterns. In the Phase 2 trial, 100% of participants lost ≥5% of body weight at both the 8 mg and 12 mg dose levels. Approximately 83% of the 12 mg group achieved ≥15% weight loss, compared to ~77% at 8 mg and ~75% at 4 mg. The placebo group saw only ~2.1% average weight loss. These numbers demonstrate both the dose dependent effect on efficacy and the fact that even moderate doses deliver significant weight loss.

Critical Safety Concerns and Medical Supervision Requirements

If you've read this far, you understand the clinical dosing structure. Now here's the part that matters most: why you cannot safely do this without a doctor, and why the source of your medication is a life-or-death decision.

Research Peptide Dangers

The unregulated "research peptide" market is flooded with products labeled as retatrutide that have never been tested for human use, quality, or safety. Investigative reporting and independent lab testing have revealed alarming failure rates: up to 10 to 20% of tested "retatrutide" samples from underground sources failed basic quality metrics including sterility, purity, or dose consistency.

This means the product you inject might contain:

• Wrong doses-too much or too little active compound, making any dosage chart meaningless

• Bacterial contamination-sterility failures that can cause injection-site infections or systemic illness

• Unknown impurities-synthesis byproducts or degradation compounds with unpredictable effects on your liver function, kidney function, and cardiovascular system

Beyond the health risks, purchasing and self-administering an unapproved investigational drug outside of clinical trials carries significant legal and medical risk.

Why Doctor Supervision Is Non-Negotiable

Retatrutide dosing is not a one-size-fits-all protocol. Your physician needs to:

• Assess your baseline health before the first injection: comprehensive metabolic panel, liver enzymes, kidney function, lipid panel, HbA1c, and cardiovascular evaluation

• Evaluate drug interactions with other medications you may be taking-retatrutide's effects on gastric emptying and blood sugar can alter the absorption and efficacy of numerous other drugs

• Monitor your individual response at each dose step: What works for a 300 lb male with metabolic syndrome is completely different from what's appropriate for a 180 lb female with borderline BMI

• Manage side effects proactively: persistent nausea, vomiting, diarrhea, or elevated heart rate may require holding at a current dose, extending the titration process, or establishing a lower target maintenance dose

• Track organ function longitudinally: liver and kidney markers need repeat testing, especially at higher dose groups where metabolic stress increases

The titration process is inherently a medical procedure. Each dose increase is a clinical decision that depends on how your body responded to the previous one.

Why pharmacy claims are not a shortcut

While retatrutide remains investigational, a compounding claim should not be treated as a legal shortcut around clinical-trial access. FDA has warned against unapproved GLP-1 products marketed online, and compounded drugs are not FDA-approved products. A safer evaluation should focus on whether the product is legally available, who is supervising care, and whether an approved alternative is more appropriate today.

For any GLP-1 or peptide conversation, the quality questions still matter:

• Legal status: is this an approved medication, a properly prescribed compounded medication where allowed, or an investigational compound?

• Verified potency and sterility: can the source document quality controls, pharmacy identity, and handling standards?

• Provider supervision: is a licensed clinician reviewing health history, contraindications, side effects, and follow-up?

This is not the same as ordering from a website that sells "research chemicals" with disclaimers stating the product is "not for human consumption." Those disclaimers do not make a product safe, legal, or appropriate for injection into a human being.

Conclusion and Next Steps

Retatrutide dosage charts from the TRIUMPH program and earlier Phase 2 trial show a consistent principle: start at 2 mg, increase by approximately 2 to 3 mg every four weeks through gradual dose increases, and reach a target maintenance dose of 4 mg, 9 mg, or 12 mg based on individual response and tolerability. The clinical research demonstrates extraordinary weight loss results-up to 28.7% of body weight over 68 to 80 weeks at the highest dose. But every number in those trial protocols was achieved under rigorous medical supervision, with carefully screened participants, regular lab monitoring, and physician-directed dosing decisions.

Your immediate next steps should be:

1. Consult a qualified healthcare provider who specializes in weight management-not a website selling research chemicals

2. Ask about approved options first including semaglutide, tirzepatide, nutrition support, resistance training, and whether a clinical trial is realistic

3. Check ClinicalTrials.gov or Lilly's trial finder if your specific interest is retatrutide access while it remains investigational

4. Commit to ongoing monitoring for any GLP-1 or next-generation obesity treatment-this is not a "set it and forget it" category

Get Pep'd telehealth services offer provider-reviewed consultations for patients with questions about weight-loss care, GLP-1 options, peptide education, and safety. Get Pep'd does not sell gray-market research retatrutide vials, and retatrutide itself remains investigational.

For readers interested in related topics, understanding how retatrutide fits within the broader landscape of hormone optimization and metabolic health-including how its three hormone pathways interact with your body's existing metabolic systems-can help you have a more informed conversation with your physician about whether this therapy is appropriate for your goals.

This content is for educational purposes and is not medical advice. Retatrutide is investigational and not FDA-approved for any use. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Trial figures cited here are average results from the named clinical trials, not a promise of individual results. A licensed provider determines whether any treatment is appropriate for you. Results vary.